Company Profile

Arvinas Inc
Profile last edited on: 11/16/2023      CAGE: 735Y7      UEI: GB1LFAEYA5P1

Business Identifier: Degradation of disease-causing cellular proteins via proteolysis
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

5 Science Park
New Haven, CT 06511
   (203) 535-1456
Location: Single
Congr. District: 03
County: New Haven

Public Profile

Arvinas is a pharmaceutical company organized around developing new small molecules ? known as PROTACs (PROteolysis TArgeting Chimeras) ? aimed at degrading disease-causing cellular proteins via proteolysis. Anchored in work initiated at Yale University by one of the Founders of the firm, the company is translating natural protein degradation approaches into novel drugs for the treatment of cancer and other diseases. The proprietary PROTAC-based drug paradigm induces protein degradation, rather than protein inhibition, using the ubiquitin proteasome system and offers the advantage of potentially targeting "undruggable" as well as "druggable" elements of the proteome. This greatly expands the ability to create drugs for many new, previously unapproachable targets. Focused on developing novel therapeutics to treat a variety of diseases including cancer, pro-inflammatory, autoimmune and rare diseases Many diseases are a result of ‘rogue’, uncontrolled proteins. Arvinas is tackling development of a new drug paradigm based on the elimination of these proteins by offering proteolysis-targeting chimera (PROTAC)-based drugs that induce protein degradation to target and eliminate disease-causing proteins from the body.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Publicly Traded
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2017 2 NIH $1,050,626
Project Title: Novel Androgen Receptor Degraders to Treat Castration-Resistant Prostate Cancer

Key People / Management

  John G Houston -- President and Chief Executive Office

  Manny Litchman -- President & Ceo

  Sean Cassidy -- Chief Financial Officer

  Andy Crew -- Senior Vice President, Chemistry

  Craig Crews -- Founder & Chief Scientific Advisor

  Marcia Dougan Moore -- Vice President of Development Operations

  John A Grosso -- Vice President of Chemistry, Manufacturing, and Controls

  Ian Taylor -- Senior Vice President, Biology

  Steve Weiss -- VP Human Resources